The relationship between obesity and cognitive health and decline
The relationship between obesity and cognitive impairment is important given the globally
ageing population in whom cognitive decline and neurodegenerative disorders will carry …
ageing population in whom cognitive decline and neurodegenerative disorders will carry …
Inflammation and oxidative stress: the molecular connectivity between insulin resistance, obesity, and Alzheimer's disease
Type 2 diabetes (T2DM), Alzheimer's disease (AD), and insulin resistance are age‐related
conditions and increased prevalence is of public concern. Recent research has provided …
conditions and increased prevalence is of public concern. Recent research has provided …
Hyperinsulinemia drives diet-induced obesity independently of brain insulin production
AE Mehran, NM Templeman, GS Brigidi, GE Lim… - Cell metabolism, 2012 - cell.com
Hyperinsulinemia is associated with obesity and pancreatic islet hyperplasia, but whether
insulin causes these phenomena or is a compensatory response has remained unsettled for …
insulin causes these phenomena or is a compensatory response has remained unsettled for …
Human alcohol-related neuropathology
SM De La Monte, JJ Kril - Acta neuropathologica, 2014 - Springer
Alcohol-related diseases of the nervous system are caused by excessive exposures to
alcohol, with or without co-existing nutritional or vitamin deficiencies. Toxic and metabolic …
alcohol, with or without co-existing nutritional or vitamin deficiencies. Toxic and metabolic …
The role of type 2 diabetes in neurodegeneration
A growing body of evidence links type-2 diabetes (T2D) with dementia and
neurodegenerative diseases such as Alzheimer's disease (AD). AD is the most common …
neurodegenerative diseases such as Alzheimer's disease (AD). AD is the most common …
NOX enzymes in the central nervous system: from signaling to disease
S Sorce, KH Krause - Antioxidants & redox signaling, 2009 - liebertpub.com
Oxidative stress has been implicated in the pathogenesis of neurologic and psychiatric
diseases. The brain is particularly vulnerable to oxidative damage due to high oxygen …
diseases. The brain is particularly vulnerable to oxidative damage due to high oxygen …
Drug repositioning for Alzheimer's disease
A Corbett, J Pickett, A Burns, J Corcoran… - Nature reviews Drug …, 2012 - nature.com
Existing drugs for Alzheimer's disease provide symptomatic benefit for up to 12 months, but
there are no approved disease-modifying therapies. Given the recent failures of various …
there are no approved disease-modifying therapies. Given the recent failures of various …
Evaluating the effects of the novel GLP-1 analogue liraglutide in Alzheimer's disease: study protocol for a randomised controlled trial (ELAD study)
GD Femminella, E Frangou, SB Love, G Busza… - Trials, 2019 - Springer
Background Liraglutide is a glucagon-like peptide-1 (GLP-1) analogue currently approved
for type 2 diabetes and obesity. Preclinical evidence in transgenic models of Alzheimer's …
for type 2 diabetes and obesity. Preclinical evidence in transgenic models of Alzheimer's …
[HTML][HTML] Protein tyrosine phosphatase 1B (PTP1B) as a potential therapeutic target for neurological disorders
J Olloquequi, A Cano, E Sanchez-López… - Biomedicine & …, 2022 - Elsevier
Protein tyrosine phosphatase 1B (PTP1B) is a typical member of the PTP family, considered
a direct negative regulator of several receptor and receptor-associated tyrosine kinases …
a direct negative regulator of several receptor and receptor-associated tyrosine kinases …
Diabetes as a risk factor for Alzheimer's disease: insulin signalling impairment in the brain as an alternative model of Alzheimer's disease
C Hölscher - 2011 - portlandpress.com
Surprisingly little is known about the mechanisms that trigger the onset of AD (Alzheimer's
disease) in sporadic forms. A number of risk factors have been identified that may shed light …
disease) in sporadic forms. A number of risk factors have been identified that may shed light …